HAMPTON, N.J., May 5, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it will present results from a recent pig study evaluating the effect of its Bioabsorbable Cardiac Matrix (BCM) on the mechanics of the heart following a heart attack. The results will be presented at the Clinical Forum of the European Society of Cardiology's Heart Failure 2015/2nd World Congress on Acute Heart Failure, being held in Seville, Spain from May 23 - May 26, 2015. The poster details are as follows:
Title: Intracoronary artery deployment of a bioabsorbable cardiac matrix (BCM) alginate device improves mechanics of the infarct region in pigs
Date: Saturday, May 23, 2015
Session: Clinical Forum
Time: 8:30am CET
Presenter: Martin D. Meglasson, Ph.D., Chief Scientific Officer, Bellerophon Therapeutics
About BCM
BCM is an injectable device currently undergoing a double-blind, placebo controlled trial (PRESERVATION-1) for the prevention of cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction (AMI), commonly known as a heart attack. The trial, which completed enrollment in December 2014 and is expected to report top-line results in mid-2015 following a six month evaluation period for all patients, is a CE mark registration trial in the European Union and is comparable to a Phase 2 trial in United States.
More than 1.9 million patients in the United States and European Union suffer a heart attack each year, of which approximately 35-40% develop congestive heart failure within five years of the event. Bellerophon Therapeutics' BCM is a liquid medical device that is intended to prevent congestive heart failure after a heart attack. BCM is administered through an injection into the coronary artery, leading to the damaged area of the heart, after an AMI. The injection is made during a minimally invasive procedure called percutaneous coronary intervention (PCI), a procedure which is commonly used when opening up cardiac blood vessels in patients requiring a stent.
Once BCM is deployed, it flows into damaged heart muscle where it forms a gel which acts as a protective meshwork, or scaffold, within the wall of the heart's left ventricle. This flexible scaffold provides physical support to the heart wall and prevents further damage, while the heart heals, after the AMI. BCM is bioabsorbable and eliminated from the body after the heart heals. Bellerophon has an exclusive worldwide license to BCM from BioLineRx Ltd.
About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. Two of the company's product candidates are based on its proprietary pulsatile nitric oxide delivery device, INOpulse, one for the treatment of pulmonary arterial hypertension (PAH) and a second for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). Bellerophon's other program is bioabsorbable cardiac matrix, or BCM, which is being developed for the prevention of cardiac remodeling and subsequent chronic heart failure following acute myocardial infarction (AMI), commonly known as a heart attack. For more information, visit www.bellerophon.com.
Forward-looking Statements
Any statements in this press release about Bellerophon's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent Bellerophon's views only as of the date of this press release. Bellerophon anticipates that subsequent events and developments will cause its views to change. While Bellerophon may elect to update these forward-looking statements at some point in the future, Bellerophon specifically disclaims any obligation to do so.
CONTACT: At Bellerophon:
Manesh Naidu, Chief Business Officer
(908) 574-4770
At Rx Communications Group:
Paula Schwartz (Investors)
(917) 322-2216
Eric Goldman (Media)
(917) 322-2563
egoldman@RxIR.com
Bellerophon Therapeutics LLC